Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 2
2018 1
2019 3
2020 6
2021 7
2022 13
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0 …
Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse e …
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG. Bardia A, et al. Future Oncol. 2019 Oct;15(28):3209-3218. doi: 10.2217/fon-2019-0370. Epub 2019 Aug 20. Future Oncol. 2019. PMID: 31426673 Free article.
Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD) that has demonstrated activity in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer previously treated with endocrine therapies including fulvestra …
Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD) that has demonstrated activity …
Elacestrant: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Apr;83(6):555-561. doi: 10.1007/s40265-023-01861-0. Drugs. 2023. PMID: 37060385 Free PMC article. Review.
Development of elacestrant for the treatment of vasomotor symptoms has been discontinued. This article summarizes the milestones in the development of elacestrant leading to this first approval for this indication....
Development of elacestrant for the treatment of vasomotor symptoms has been discontinued. This article summarizes the milestones in t …
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Bardia A, et al. J Clin Oncol. 2021 Apr 20;39(12):1360-1370. doi: 10.1200/JCO.20.02272. Epub 2021 Jan 29. J Clin Oncol. 2021. PMID: 33513026 Free PMC article. Clinical Trial.
PURPOSE: This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastat …
PURPOSE: This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen recep …
Pharmacology and pharmacokinetics of elacestrant.
Beumer JH, Foldi J. Beumer JH, et al. Cancer Chemother Pharmacol. 2023 Aug;92(2):157-163. doi: 10.1007/s00280-023-04550-7. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314500
Elacestrant is a dose-dependent mixed ER agonist/antagonist, which at high doses acts as a direct ER antagonist as well as selective downregulator of ER. ...Overall, elacestrant is the first orally bioavailable SERD approved by the FDA for use in patients with metas …
Elacestrant is a dose-dependent mixed ER agonist/antagonist, which at high doses acts as a direct ER antagonist as well as selective …
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.
Varella L, Cristofanilli M. Varella L, et al. Onco Targets Ther. 2023 Mar 23;16:189-196. doi: 10.2147/OTT.S400563. eCollection 2023. Onco Targets Ther. 2023. PMID: 36993871 Free PMC article. Review.
Preclinical data suggested greater efficacy of elacestrant in combination with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) or everolimus. ...Importantly, there was also a significant benefit in patients with ESR1 mutations, which led to the FDA approval of elacestr …
Preclinical data suggested greater efficacy of elacestrant in combination with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) or ev …
Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer.
Hageman E, Lussier ME. Hageman E, et al. Ann Pharmacother. 2023 Oct 27:10600280231206131. doi: 10.1177/10600280231206131. Online ahead of print. Ann Pharmacother. 2023. PMID: 37888769 Review.
Elacestrant is currently being studied in CDK 4/6 inhibitor naive patients and as a component of combination therapy for first-line use which could lead to future indications. CONCLUSIONS: Elacestrant gained FDA approval in January 2023 and can be considered in pati …
Elacestrant is currently being studied in CDK 4/6 inhibitor naive patients and as a component of combination therapy for first-line u …
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, Criscitiello C. Corti C, et al. Cancer Treat Rev. 2023 Jun;117:102569. doi: 10.1016/j.ctrv.2023.102569. Epub 2023 Apr 28. Cancer Treat Rev. 2023. PMID: 37146385 Review.
In this context, novel oral selective estrogen receptor degraders (SERDs) and other next-generation ETs are being investigated, both as single agents and in combination with targeted therapies. Elacestrant, the next generation ET in most advanced clinical development and t …
In this context, novel oral selective estrogen receptor degraders (SERDs) and other next-generation ETs are being investigated, both as sing …
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer.
Mittal A, Molto Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney SM, Tarantino P. Mittal A, et al. Cancers (Basel). 2023 Mar 28;15(7):2015. doi: 10.3390/cancers15072015. Cancers (Basel). 2023. PMID: 37046675 Free PMC article. Review.
In this setting of high unmet need, several clinical trials of novel drugs have recently reported encouraging results: the addition of the AKT-inhibitor capivasertib to fulvestrant demonstrated a significant improvement in progression-free survival (PFS); the oral selective estro …
In this setting of high unmet need, several clinical trials of novel drugs have recently reported encouraging results: the addition of the A …
62 results